This Week in CRC Research — November 15, 2026
Weekly colorectal cancer research intelligence
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Week of November 08 — November 15, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
This Week in CRC Research
RESEARCH
Gut bacteria engineered to convert cholesterol into a tumor-suppressing metabolite show promise in preclinical colorectal cancer models — Nature: Colorectal Cancer
Researchers identified a cholesterol metabolite called 4-cholesten-3-one (4-C-3) that is depleted in colorectal cancer and can suppress tumor growth by blocking EGFR (epidermal growth factor receptor) activation and stabilizing mutant KRAS in an inactive state. In preclinical models, restoring 4-C-3 using either a naturally occurring gut bacterium or an engineered non-pathogenic Escherichia coli lowered intratumoral cholesterol and induced tumor regression without overt toxicity. The approach overcame KRAS-driven resistance to anti-EGFR therapy in laboratory models.
What this means
This preclinical work suggests a novel route to target colorectal cancer through the gut microbiome, particularly for tumors carrying KRAS mutations that typically resist standard therapies. Whether microbiome engineering can be translated safely and effectively into clinical practice remains an open question.
RESEARCH
Silencing DNA repair genes with nanoparticles restores immune response in microsatellite-stable colorectal cancer — Molecular Cancer
Microsatellite-stable (MSS) colorectal cancer, which represents the majority of cases, typically does not respond to immunotherapy because it has a low tumor mutational burden. Researchers developed lipid nanoparticles carrying small interfering RNA (siRNA) that silence key mismatch repair genes (MLH1, MSH2, and MSH6), achieving over 70% gene silencing in mouse models of MSS colorectal cancer. When combined with oxaliplatin chemotherapy, this approach substantially increased tumor mutational burden, expanded the repertoire of tumor-derived neoantigens, and promoted CD8+ T cell infiltration and activation. This combinatorial regimen effectively inhibited tumor progression in pMMR/MSS CRC across both subcutaneous and liver metastasis mouse models.
What this means
This preclinical strategy offers a potential path to make the majority of colorectal cancers, those that are microsatellite-stable, responsive to immunotherapy by artificially increasing their mutational burden. The approach remains investigational and has not yet been tested in human trials.
TRIAL DATA
Phase III trial shows survival benefit for tyrosine kinase inhibitor plus immunotherapy in pretreated microsatellite-stable colorectal cancer — ESMO Gastrointestinal Oncology
The interim analysis of the phase III STELLAR-303 trial demonstrated an overall survival benefit with the combination of zanzalintinib (a tyrosine kinase inhibitor, or TKI) plus atezolizumab (an immune checkpoint inhibitor) compared with regorafenib in pretreated microsatellite-stable colorectal cancer. Tyrosine kinase inhibitors can induce immunological reprogramming of the tumor microenvironment, promoting proinflammatory macrophage polarization, antigen presentation, vascular normalization, and T-cell infiltration, which may help overcome the intrinsic resistance of MSS tumors to immunotherapy.
What this means
This is the first phase III trial to show a survival advantage for combining a tyrosine kinase inhibitor with immunotherapy in microsatellite-stable colorectal cancer, a population that has historically not benefited from immunotherapy alone. The role of liver metastases in modulating response remains an area of active investigation.
SCREENING
Positive stool DNA test still yields advanced neoplasia in one in five patients with a prior normal colonoscopy — Clinical and Translational Gastroenterology
A registry-based analysis from the New Hampshire Colonoscopy Registry compared colonoscopy outcomes after positive multitarget stool DNA (mt-sDNA) tests in 739 patients with a prior normal colonoscopy and 994 patients without a prior colonoscopy. Patients with a prior normal colonoscopy were approximately half as likely to have more advanced findings (odds ratio 0.51; 95% CI 0.41–0.62; P < 0.001), but the absolute prevalence of advanced colorectal neoplasia among patients with a previous colonoscopy remained substantial at 19.1% (95% CI 16.3–22.1%).
What this means
Even after a recent normal colonoscopy, a positive stool DNA test warrants follow-up colonoscopy, as nearly one in five such patients still harbor advanced neoplasia. Potentially reflecting lesions missed on the prior exam or rapid interval growth.
Clinical Trials Update
Covered in this week's findings: STELLAR-303 phase III trial showing overall survival benefit for zanzalintinib plus atezolizumab versus regorafenib in pretreated microsatellite-stable colorectal cancer.
By the Numbers
19.1%
The prevalence of advanced colorectal neoplasia among patients with a prior normal colonoscopy who subsequently tested positive on a multitarget stool DNA test, according to a registry-based analysis from the New Hampshire Colonoscopy Registry. This finding underscores that a positive stool DNA test warrants follow-up colonoscopy even in patients who recently had a normal exam, potentially reflecting lesions missed on the prior colonoscopy or rapid interval growth.
Resources
No patient resource reported this week in the sources read.
Questions this raises for a care team
- For microsatellite-stable colorectal cancer with liver metastases, whether the presence of hepatic disease modulates response to tyrosine kinase inhibitor plus immunotherapy combinations, and whether this should inform treatment sequencing, remains an open question.
- For tumors carrying KRAS variants outside the target regions of standard tissue PCR assays (such as L19F, A59T, and A146T), whether plasma-based sequencing should be routinely incorporated to guide anti-EGFR therapy decisions is an area requiring further validation.
- For patients with a positive multitarget stool DNA test following a recent normal colonoscopy, whether the nearly 20% prevalence of advanced neoplasia reflects primarily missed lesions versus rapid interval growth, and what this implies for colonoscopy quality benchmarks, is a question for further investigation.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data